CytoDyn Inc. (CYDY)
CytoDyn Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Vancouver, WA, US. The stock last traded at $0.23, up 12.09% on the session, giving a market capitalisation of $315.0M. On trailing twelve-month figures it carries a trailing P/E of -6.71, a net margin of 0.0%. Its beta of 1.24 implies it has historically moved more than the broad market.
CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humanized monoclonal antibody designed to interact with the CCR5 receptor. This experimental drug is being explored for its potential applications in human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), various oncological diseases, and coronavirus disease (COVID-19). In addition, leronlimab is undergoing a Phase 1b/2 clinical investigation specifically for metastatic triple-negative breast cancer. Established in 2002, and previously operating as RexRay Corporation, CytoDyn Inc. is headquartered in Vancouver, Washington.
CytoDyn Inc. is most often compared with the following Healthcare names: